<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NGS</title>
	<atom:link href="http://www.stockbloghub.com/tag/ngs/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GHDX) Genomic Health to Showcase Key Data</title>
		<link>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809</link>
		<comments>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:13:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[NGS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87809</guid>
		<description><![CDATA[Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX breast cancer test. The test is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit. Although the Oncotype DX colon cancer test was launched in 2010, it is yet to make a significant contribution to the top line. Genomic Health has undertaken several studies to expand the use of Oncotype DX. The company is studying the utility of the Oncotype DX test in patients with ductal carcinoma in situ (DCIS). Preliminary results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Ties Up with Pharma Majors</title>
		<link>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570</link>
		<comments>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[Neuberger Berman High Yield Strategies Fund]]></category>
		<category><![CDATA[NGS]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77570</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&#38;D divisions of AstraZeneca (AZN) and Johnson &#38; Johnson (JNJ). The group expects this grant to fund the development of a commercial multi-gene next generation sequencing test, which will provide comprehensive molecular profiles of tumors and identify treatment options. Life Technologies believes that the test will increase the speed and accuracy of cancer treatment. With the application of the next generation sequencing (NGS) and informatics, this genomic test will be commercially available in the global market. This program will attract additional pharmaceutical clinical trial investments in UK that should prove to be a major source of international investment. Thus, the consortium expects this new program to add life to the economic condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NGS) &#8211; surprised on estimates 4 quarters in a row by an average of 18.70% despite difficult economic conditions</title>
		<link>http://www.stockbloghub.com/2009/07/17/ngs-natural-gas-services-group-inc-value-zacks-rank-buy/10640</link>
		<comments>http://www.stockbloghub.com/2009/07/17/ngs-natural-gas-services-group-inc-value-zacks-rank-buy/10640#comments</comments>
		<pubDate>Fri, 17 Jul 2009 17:24:50 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil and Gas Equipment and Services]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[NGS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10640</guid>
		<description><![CDATA[Natural Gas Services Group, Inc. (NGS), a provider of compressors to the natural gas industry, has surprised on estimates 4 quarters in a row by an average of 18.70% despite difficult economic conditions as natural gas prices have plunged. The company is trading with a forward P/E of 12.66. Company Description Natural Gas Services Group manufactures, maintains and rents natural gas compressors that assist with the production of natural gas wells. The company also sells custom fabricated compressors and sells flare systems for gas plant and production facilities. NGS has manufacturing facilities in Tulsa, OK, Lewiston, MI and Midland, TX. NGS Surprised by 19.23% in the First Quarter On May 8, Natural Gas Services Group reported first quarter 2009 results that easily beat Wall Street estimates by 5 cents a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/17/ngs-natural-gas-services-group-inc-value-zacks-rank-buy/10640/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

